Genocea Biosciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genocea Biosciences Inc announces closing of initial public offering
Genocea Biosciences Inc:Closes initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share.Says after underwriting discounts and commissions and estimated offering expenses, Genocea received net proceeds of about $61.4 million, excluding estimated offering expenses.Shares are listed on the NASDAQ Global Market under the ticker symbol GNCA.Citigroup and Cowen and Company are acting as joint book-running managers for the offering.Stifel is acting as lead manager and Needham & Company, LLC is acting as co-manager.
Latest Developments for Genocea Biosciences Inc
- Genocea Biosciences Inc announces pricing of initial public offering
- Genocea Biosciences Inc files registration statement for proposed IPO
- Genocea Biosciences Inc appoints Chairman
- Genocea Biosciences Inc reports positive initial phase 1/2a results for gen-003, its pioneering therapeutic vaccine candidate for the treatment of Herpes Simplex Virus-2 (HSV-2), AT ICAAC 2013
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this